Anorexia Nervosa
Recent clinical, regulatory, research and industry developments relating to this disease.
Not niche: eating disorders as an example in the dangers of overspecialisation.
Anorexia nervosa and adrenal hormones: a systematic review and meta-analysis.
Endocrinology of Underweight and Anorexia Nervosa.
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.
Current Discoveries and Future Implications of Eating Disorders.
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q3 2026.
- Q3 2026Metreleptin in Anorexia Nervosa, Randomized Controlled Trial; Effects on Depressive Symptoms and Concomitant Changes in Brain Connectivity
- Q4 2026The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults
- Q3 2028Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa
- Q4 2029Study of Psilocybin for Anorexia in Young Adults
Clinical MilestonesViewHide
- 2025-12-16Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot StudyResults posted
- 2025-11-04Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot StudyResults posted
- 2026-05-18Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia NervosaResults expected Q3 2028
- 2026-03-06The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsResults expected Q4 2026
- 2026-03-03Study of Psilocybin for Anorexia in Young AdultsResults expected Q4 2029
- 2026-01-15Metreleptin in Anorexia Nervosa, Randomized Controlled Trial; Effects on Depressive Symptoms and Concomitant Changes in Brain ConnectivityResults expected Q3 2026
- 2028-08-10ClinicalAn Open-Label, Multi-Site Phase 2 Study of the Safety and Feasibility of MDMA-Assisted Psychotherapy for Eating DisordersWithdrawn
- 2026-05-18ClinicalTransdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia NervosaResults expected Q3 2028
- 2026-03-06ClinicalThe Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsResults expected Q4 2026
- 2026-03-03ClinicalStudy of Psilocybin for Anorexia in Young AdultsResults expected Q4 2029
- 2026-01-15ClinicalMetreleptin in Anorexia Nervosa, Randomized Controlled Trial; Effects on Depressive Symptoms and Concomitant Changes in Brain ConnectivityResults expected Q3 2026
- 2025-12-16ClinicalEffects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot StudyResults posted
- 2025-11-04ClinicalEffects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot StudyResults posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Anorexia Nervosa10
- Bulimia Nervosa3
- Feeding and Eating Disorders3
- Major Depressive Disorder3
- Binge-Eating Disorder2
- Autism Spectrum Disorder1
- Bipolar Disorder1
- Bulimia1
Leading journals6
- Translational psychiatry2
- Archives of general psychiatry1
- BMC psychiatry1
- European journal of endocrinology1
- European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology1
- International journal of environmental research and public health1
Leading researchers8
- Andreassen OA2
- Bulik CM2
- Kaye WH2
- Adan RAH1
- Alfredsson L1
- Ando T1
- Arcelus J1
- Babakanian A1
Affiliations (unnormalised)6
- Institute of Psychiatry2
- Karolinska Institutet2
- Norwegian Institute of Public Health2
- University of Bristol2
- University of California2
- University of California San Diego2
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Anorexia nervosa is an eating disorder marked by loss of appetite, intense fear of becoming overweight, disturbance in body image, significant weight loss, and refusal to maintain a minimally normal weight. It is described as occurring most often in adolescent females, and it can have serious physical, psychological, and social consequences.
The supplied grounding does not identify a single established cause. It supports a psychiatric and psychological framing, with literature also addressing genetics and the role of distressing thoughts and emotions, but it does not specify a definitive aetiology.
The grounding describes anorexia nervosa as involving self-induced negative energy balance and the biological effects of starvation and low body weight. Reported physiopathology includes endocrine changes associated with malnutrition and underweight, altered adrenocortical hormones, and disturbances in hunger and satiety regulation. Literature also discusses compulsive exercise and overlap with obsessive-compulsive mechanisms as part of the disorder's neurobiological underpinnings.
Adolescence and female sex are the clearest risk-associated features supported by the grounding, since the disorder occurs most frequently in adolescent females. The literature also notes that eating disorders often develop during adolescence or early adulthood and are associated with preoccupation with food, body weight, and shape, but it does not establish these as causal risk factors.
Treatment is generally described as a combination of therapy, nutrition counseling, and medical care. The grounding also supports psychotherapy and drug therapy as literature-covered modalities, but it does not specify a standard medication class for anorexia nervosa. Review literature further discusses emerging or experimental approaches such as psychedelic-assisted therapy, but these are not established standard care in the supplied material.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.